Table 2.
Distribution of patient characteristics of the combined study MAMMARAND
| Prognostic variables | MAMMARAND | WPS | |||
|---|---|---|---|---|---|
| Iscador | Control | P | |||
| n = 55 | n = 55 | ||||
| Matching variables | FIGO | TNM | |||
| I | T1aN0M0 | 23 | 23 | ||
| IIA | T2N0M0 | 7 | 7 | ||
| IIB | T3N0M0 | 8 | 8 | ||
| IIIA | T2N2M0 | 1 | 1 | ||
| T3N1–2M0 | 5 | 5 | |||
| IIIB | T4N1–4M0 | 10 | 10 | ||
| T3N3M0 | 1 | 1 | |||
| Grading | |||||
| 1 | 26 | 26 | |||
| 2 | 3 | 3 | |||
| 3 | 4 | 4 | |||
| NA | 22 | 22 | |||
| Menopause | |||||
| Prae | 12 | 12 | |||
| post | 5 | 5 | |||
| NA | 38 | 38 | |||
| Age at first diagnosis | |||||
| Mean | 50.22 | 50.31 | |||
| SD | 7.56 | 7.69 | |||
| Range | 33–63 | 34–62 | |||
| Conventional therapy | |||||
| Operation | 55 | 54 | |||
| Chemotherapy | 24 | 25 | |||
| Radiotherapy | 25 | 27 | |||
| Hormone therapy | 9 | 16 | |||
| Baseline variable | Self-regulation | 0.51 | |||
| Mean/median | 3.63/3.70 | 3.54/3.60 | |||
| SD | 0.80 | 0.76 | |||
| Range | 1.7–5.5 | 1.7–5.5 | |||
| Therapy variable | Iscador use (years) | ||||
| Mean/median | 8.47/7.00 | NA | |||
| SD | 5.84 | ||||
| Range | 0.08–20.83 | ||||
Abbreviations: WPS, Wilcoxon paired sample test; SD, standard deviation; NA, not available.